Syndax Pharmaceuticals, Inc. Common Stock (SNDX) Stock
Key stats
- Market cap
- $863.37M
- Price / Earnings ratio
- -4.1x
- EPS (TTM)
- -$2.36
- Volume
- Loading
- 52-week high
- $25.59
- 52-week low
- $9.15
Source: third-party data provider, as of November 13, 2026
Compare with SNDX
Recent news

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
SNDX

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
SNDX

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
SNDX

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
SNDX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 26.74
- MACD 12/26/9
- -1.75
- EMA 9 of MACD
- -1.49
- MACD histogram
- -0.26
- SMA 50
- $15.72
- Price below SMA 50
- EMA 50
- $14.89
- Price below EMA 50
- SMA 200
- $19.83
- Price below SMA 200
- EMA 200
- $18.69
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.30 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
SNDX

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
SNDX

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
SNDX

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
SNDX

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
SNDX

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?
SNDX

Syndax Pharmaceuticals Q2 Earnings Call Highlights
Syndax Pharmaceuticals Q2 Earnings Call Highlights
SNDX

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
SNDX

Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
SNDX

Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
SNDX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Syndax Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael A. Metzger M.B.A. | CEO & Director | 1971 |
| Mr. Keith Alan Goldan CPA | CFO, Treasurer & Principal Accounting Officer | 1971 |
| Mr. Luke J. Albrecht J.D. | General Counsel & Corporate Secretary | 1979 |
| Mr. Steven Closter | Chief Commercial Officer | 1969 |
| Dr. Nicholas A.J. Botwood B.Sc., MBBS | Head of Research & Development and Chief Medical Officer | 1968 |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder | 1957 |
| Dr. Michael Downes Ph.D. | Co-Founder | — |
| Sharon Klahre | Vice President of Investor Relations & Communications | — |
| Ms. Averi Price | Senior VP of Legal & Chief Compliance Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 26.74
- MACD 12/26/9
- -1.75
- EMA 9 of MACD
- -1.49
- MACD histogram
- -0.26
- SMA 50
- $15.72
- Price below SMA 50
- EMA 50
- $14.89
- Price below EMA 50
- SMA 200
- $19.83
- Price below SMA 200
- EMA 200
- $18.69
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $33.00
- Average
- $34.50
- High
- $36.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.7 | +43.7 | ||||||||||
| 2022 | -26.2 | -6.1 | +8.2 | -4.8 | -4.0 | +16.1 | +6.8 | +15.8 | -2.8 | -4.8 | +3.6 | +1.7 |
| 2023 | +12.1 | -12.5 | -15.0 | -1.7 | -5.1 | +3.8 | +2.2 | -12.4 | -25.7 | +4.3 | +19.6 | +30.4 |
| 2024 | -6.3 | +10.4 | +0.4 | -11.1 | -12.3 | +6.4 | +5.4 | -6.6 | -6.3 | -5.2 | -11.9 | -20.8 |
| 2025 | +0.6 | +9.1 | -20.6 | +17.8 | -23.7 | -14.7 | +12.5 | +63.6 | -4.5 | -12.6 | +44.0 | +9.9 |
| 2026 | -4.6 | +1.7 | +5.5 | -10.3 | +2.5 | +16.0 | -8.8 | +0.3 | -6.5 | -25.1 | -26.8 |



